Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market

Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market